Pulmonary hypertension (PH) is a recently recognized complication of chronic kidney disease (CKD), especially in end-stage renal disease. It has prevalence estimates of 30%-50% and is an independent predictor of increased mortality in CKD patients. The aim of this study is to analyze the prevalence of PH in patients with CKD, its severity in different stages of CKD, and risk factors for it. One hundred and eight patients with CKD treated at Karnataka Institute of Medical Sciences, Hubli, Karnataka, between January 1, 2014, and June 30, 2015, were selected. Clinical evaluation and relevant investigations including echocardiography were done. Follow-up echocardiography was done at 3 and 6 months and assessed. The mean age of studied population was 43.53 ± 14.63 years. Sex ratio was 2.72:1 (male:female). PH was present in 47 of 108 (43.5%) cases at beginning, 41 of 83 (491.4%) at 3 months, and 32 of 64 (50%) at 6 months. The prevalence and severity of PH increased with progression of CKD stage, although not statistically significant. Heart failure with reduced ejection fraction and heart failure with preserved EF were significantly higher among PH group compared to non-PH group (P < 0.01). Mean hemoglobin in PH group was significantly lower, compared to non-PH group (P < 0.01). Mean interdialytic weight gain and central venous pressure were higher among PH group than non-PH group. Higher calcium phosphate product ≥50 was more prevalent in PH group than in non-PH group. The majority of them had moderate PH at the beginning of the study which remained same, despite being on hemodialysis. PH is a common complication in CKD patients with prevalence of 43.5%-50%. Left-sided heart failure, anemia, fluid retention, and increased calcium phosphate product are the risk factors for developing PH.
Introduction
Chronic kidney disease (CKD) is a common health problem worldwide. Cardiovascular disease is the most common cause of morbidity and mortality in CKD. [1] Pulmonary hypertension (PH) is an overlooked cardiovascular complication of CKD, especially in end-stage renal disease (ESRD). The prevalence of PH in patients with ESRD ranges from 27% to 58%. [2] Patients with advanced CKD have a prevalence of PH that is lesser than that in patients with ESRD, ranging from 8% to 39%. [3] [4] [5] [6] PH is an independent predictor of increased mortality in patients with CKD. [2, 3] PH is defined as "a mean pulmonary artery pressure more than or equal to 25 mmHg at rest or 30 mmHg at exercise." The pathogenesis of PH in CKD is not fully elucidated. [2] It is considered to be due to interaction of multiple aspects of altered cardiovascular physiology. Myocardial dysfunction leading to elevated left ventricular filling pressure and pulmonary venous hypertension is the predominant cause of PH in CKD. [3, 6, 7] The other factors implicated are increased cardiac output (CO), [2, 3] increased pulmonary blood flow due to shunting across arteriovenous fistula (AVF) [3, 7] volume overload, anemia, exposure to dialysis membranes, [7] endothelial dysfunction leading to pulmonary vasoconstriction, decreased compliance of pulmonary vasculature, vascular calcification and stiffening, [7] increased thromboxane B 2 , and pro-brain natriuretic peptide. [4] This study was conducted to assess prevalence, severity and risk factors of PH in CKD.
Methods

Source of data
One hundred and eight patients with CKD treated at General Medicine, Nephrology and Cardiology wards at Karnataka Institute of Medical Sciences (KIMS), a government-run tertiary care hospital, Hubli, Karnataka, between January 1, 2014, and July 31, 2015, were considered for the study.
Sample size calculation
The sample size was estimated using the proportion of PH in CKD patients from the literature as 50%. Using the formula, = Is standard normal variate (at 5% type 1 error [P < 0.05], it is 1.96; at 1% type 1 error [P < 0.01], it is 2.58). As in majority of studies, P < 0.05 was considered statistically significant and hence 1.96 is used in the formula. p = Expected proportion in population based on previous studies or pilot studies. d = Absolute error or precision -has to be decided by researcher. P = 50; q = 50; d = 10%.
Using the above values at 95% confidence level, a sample size of 98 patients with CKD was need to be included in the study. Considering 10% non-response, a sample size of 98 + 9.8 ≈ 108 individuals were included in the study.
One hundred and twenty-five consecutive patients with CKD were evaluated for inclusion and exclusion criteria, of which 108 patients fulfilling the criteria were considered for the study. This study complies with the Declaration of Helsinki. Clearance was obtained from the Ethical Committee of KIMS, Hubli, Karnataka.
Methods of collections of data
• Selected patients were informed about objectives of the study, and informed consent was taken from the patient or their guardian • Information was collected using a preformed proforma from each patient.
Type of study
This was a prospective observational study. 
Protocol
The history was elicited with special reference to symptoms of CKD, congestive heart failure, PH, risk factor for developing CKD, comorbid conditions, duration of diagnosis of CKD, and HD. Clinical signs of CKD, heart failure, and PH were assessed. Each case underwent relevant investigations. Staging of CKD was done based on estimated glomerular filtration rate (eGFR) estimated by Modification of Diet in Renal Disease formula. Electrocardiogram (ECG) was done to look for features of PH, right ventricular (RV) strain pattern, left ventricular (LV) strain pattern, and IHD.
Echocardiography was done in all patients at the beginning of the study, 3 months, and 6 months. Pulmonary artery systolic pressure (PASP) was calculated using TR jet velocity in Doppler echocardiography and applying Bernoulli equation. A PASP value of ≥35 mmHg at rest was taken to be suggestive of PH. Echocardiography was also used to assess the LV hypertrophy, dilatation, chamber size, LV systolic function and diastolic function, LV ejection fraction (EF), regional wall motion abnormality, and pericardial effusion. Comparison was made between CKD patients with presence and absence of PH.
Statistical analysis
Descriptive and inferential statistical analysis had been carried out in the study. The continuous variables such as age, blood pressure (BP), and EF were expressed in terms of mean ± standard deviation (SD). The categorical measurements were expressed in number (percentage). Significance was assessed at 5% level of significance (P < 0.05).
Student's t-test (two-tailed, independent) has been used to find the significance of study parameters on continuous scale between two groups with presence and absence of PH (intergroup analysis) on metric parameters. Chi-square/Fisher's exact test has been used to find the significance of study parameters on categorical scale between two or more groups.
Statistical software
The statistical software, namely, SAS 9.2 (SAS institute Inc. 2010 Cary, North Carolina, USA) andSPSS 20 (version 20.0, IBM Corp. 2010 Armonk, NY, USA), were used for the analysis of the data, and Microsoft word and Excel were used to generate graphs, tables, etc.
Results
General characteristics
The mean age of the study population was 44.53 ± 14.63 years. The majority were of age group of 31-50 years (67.6%), which represent the productive age group of the society. Sex ratio was 2.6:1 [ Table 1 ]. Overview of study results are depicted in [ Figure 1 ].
Echocardiographic findings
Assessment of pulmonary hypertension
Of 108 patients who were assessed with ECHO at beginning of the study, 47 (43.5%) patients had PH. The mean PASP among patients with PH at this ECHO was 51.1 ± 13.3 mmHg. The majority had moderate PH. Table 3 ], although this was not statistically significant, since there were few patients in stage 3 and stage 4.
Among 108 patients, 57 were on thrice-weekly HD and 51 were on twice-weekly HD. Of these 57 patients on thrice-weekly HD, 24 had PH (42.1%). Of 51 on twice-weekly HD, 23 had PH (45%). There was no significant difference in prevalence of PH between these 2 groups (P = 0.85).
Assessment of other echocardiographic findings
Heart failure with reduced EF (HFrEF) was present in 29 (26.6%) of 108 patients. Among the patients with LV systolic dysfunction, majority had mild dysfunction [ Table 2 ].
The prevalence of heart failure with preserved EF (HFpEF,) was 95 (85.2%) of 108 patients at first ECHO, increased further at follow-up ECHO [ Table 2 ].
Comparison between the groups with presence and absence of pulmonary hypertension
The prevalence of clinical features of PH dyspnea, loud P 2 , and ascites were significantly higher among the patients with PH compared to those without PH [ Table 4 ].
There was no significant difference in various ECG findings between the patients with PH and without PH [ Table 4 ]. HFrEF, HFpEF, and pericardial effusion were significantly higher among the patients with PH, compared to those without PH [ Table 4 ].
Mean ± SD of central venous pressure (CVP) and interdialytic weight gain among the patients with PH was significantly higher compared to those without PH (P = 0.05 and P = 0.014, respectively). This implies that volume overload is associated with increased risk of Total  3  4  5  Absent  3  4  54  61  Mild  1  3  18  22  Moderate  0  0  23  23  Severe  0  0  2  2  Total  4  7  97 108 P=0.716, not significant. CKD: Chronic kidney disease, PH: Pulmonary hypertension PH. Dialysis duration was higher among the patients with PH than those without PH (P = 0.09) [ Table 5 ].
Mean ± SD of hemoglobin (Hb) and EF was significantly lower among the patients with PH compared to those without PH. This implies that anemia and LV failure are associated with increased risk of PH [ Table 5 ].
Outcome difference between the two groups
The mortality rate in our study population by the end of 1.5 years was 24.1% (26 of 108). It was about two times higher among the patients with PH compared to those without PH (P = 0.03) [ Figure 2 ].
Discussion
PH remained an underestimated issue in CKD patients until the very recent years. In our study, majority of the patients in all the three echocardiography had moderate PH. This is consistent with other studies.
PH in CKD can occur through multiple mechanisms, including PH of WHO Group 1-5 (pulmonary arterial hypertension, left-sided heart disease, chronic pulmonary disease and hypoxia, chronic thromboembolic disease, and unexplained PH, respectively). [2] Statistically significant risk factors for developing PH found in our study population were as follows:
• HFrEF (LV systolic failure) HFpEF (LV diastolic failure), Anemia (P = 0.003) • Calcium × phosphate product ≥50 Higher interdialytic weight gain, indicating fluid retention and volume overload (P = 0.014) • "Higher CVP, indicating fluid retention and volume overload." Role of above factors have been studied in various previous studies as depicted in Table 6 .
Role of left ventricular failure in causing pulmonary hypertension in CKD
The prevalence of heart failure in patients with CKD is 30%-40%. [10, 11] This is the most important mechanism contributing to PH (WHO Group 2) in CKD patients and has been extensively evaluated in many studies. [2, 3, 8] In our study, HFrEF was present in 20.4%. Its prevalence among the patients with and without PH was 38.3% and 6.6%, .001** LV: Left ventricular, HFrEF: Heart failure with reduced ejection fraction, HFpEF: Heart failure with preserved ejection fraction, IHD: Ischemic heart disease, TR: Tricuspid regurgitation, ECG: Electrocardiography, ECHO: Echocardiography, PH: Pulmonary hypertension. *Moderately significant ( P value:0.01<P≤0.05), **Strongly significant (P value : P≤0.01) respectively (P < 0.001). The mean EF among the patients with PH was significantly lower, compared to those without PH. This is consistent with the study by Kumbar et al. [8] and Fabbian et al. [9] HFpEF was present in 85.2% of cases. The prevalence of HFpEF was significantly higher among the patients with PH, compared to those without PH (P = 0.006). This is consistent with the study by Abdelwhab et al. [4] HFrEF and HFpEF were persistent despite being on HD in our study, thus contributing to the development of elevated LV filling pressure and pulmonary venous hypertension. Although HD corrects volume overload and removes the toxic metabolites, it did not have a significant impact on LV function and PASP.
LV failure is a multifactorial process in patients with CKD. It is caused by chronic volume overload, elevated [8] 36 PD 42 Increased serum phosphorus, parathyroid hormone, calcium × phosphate product, lower EF, dilated LV Fabbian et al. 2010 [9] 29 on HD 60±13 58.6 42±6 Diabetes, increased, dialysis duration, Interdialytic weight gain, lower DBP and EF 27 on PD 18.5 CKD: Chronic kidney disease, PASP: Pulmonary artery systolic pressure, CVP: Central venous pressure, LV: Left ventricular, ESRD: End stage renal disease, CO: Cardiac output, HD: Hemodialysis, AVF: Arteriovenous fistula, PD: Peritoneal dialysis, EF: Ejection fraction, DBP: Diastolic blood pressure mean arterial pressure, uremia-mediated cardiac myocyte dysregulation, anemia-mediated hypoxemic stress, and impairment in cardiac function by microvascular and macrovascular coronary artery disease. [12] Hypertension and diabetes mellitus, which are two dominant causes of CKD, trigger LV diastolic dysfunction, an alteration bound to increase pulmonary venous and arterial pressure. [13] However, in our study, there was no significant difference in prevalence of hypertension and diabetes mellitus between the two groups.
Persistent elevation of the PCWP owing to impaired diastolic relaxation leads to vascular remodeling with thickening of the pulmonary capillary endothelial basal lamina and proliferation of connective tissue surrounding the alveoli. A study of 76 ESRD by Abdelwhab et al. showed that patients with diastolic dysfunction have an odds ratio of 21.9 for developing PH. [4] Both proteinuria and reduction of GFR have been associated with increased cardiovascular morbidity and mortality. [13, 14] This association is so strong and clinically relevant that the diagnosis of CKD places a patient into the highest cardiovascular risk level, irrespective of stratification according to traditional cardiovascular risk factors. [14, 15] The high mortality among CKD patients on renal replacement therapy, which for the ages between 25 and 35 years may rise up to 375-fold compared to the general population, is derived predominantly from cardiovascular causes. [16, 17] This cardiovascular morbidity occurring in patients with CKD is called cardiorenal syndrome type 4, which reflects tight interlink between the heart and kidney. [18] 
Role of other factors in causing pulmonary hypertension in CKD
Lower diastolic BP (DBP) was found to be associated with PH in a study by Kumbar et al. [8] However, in our study, there was no significant difference in either DBP or systolic BP between the patients with and without PH (P = 0.383 and P = 0.659, respectively). Anemia is a common manifestation of CKD and important risk factor for developing PH found in our study. The mean Hb was significantly lower among PH group compared to non-PH group, thus implicating the role of anemia in PH. This is consistent with the study by Yigla et al. [3] and Etemadi et al. [19] In our study, Percentage prevalence of higher calcium phosphate product was significantly greater among those with PH, compared to those without PH. This is consistent with the study by Kumbar et al. [8] Increased calcium phosphate product predisposes to pulmonary vascular calcification, leading to PH. [2, 8] In our study, interdialytic weight gain and CVP were significantly higher among the patients with PH, compared to those without PH This is consistent with the study by Fabbian et al. [9] This suggests fluid retention to be a contributing factor for developing PH.
Role of hemodialysis in pulmonary hypertension in chronic kidney disease
In our study, the mean dialysis duration was found to be higher among the patients with PH than those without PH. This is consistent with the study by Fabbian et al. [9] The pathogenic mechanisms proposed for PH in CKD patients on hemodialysis are AVF-induced, increased CO, which cannot be accommodated by pulmonary circulation. In addition, pulmonary vessels show signs of endothelial dysfunction resulting in dysregulation of vascular tone due to an imbalance between vasodilators, such as prostacyclins and nitric oxide (NO), and vasoconstrictors, such as endothelin-1, plasma asymmetric dimethylarginine, and thromboxane B 2 , and local as well as systemic inflammation. It is also believed that microbubbles escaping from the dialysis circuit can trigger vasoconstriction and vascular sclerosis. [4, 20] There was no significant difference in PH prevalence between those who had thrice-weekly and twice-weekly HD. Whether improving the frequency and quality of HD improves heart failure and hence PH is still an unanswered issue and further studies are needed in this regard.
Outcome difference in CKD patients between the groups with presence and absence of pulmonary hypertension
The mortality rate among those with PH was significantly higher, compared to those without PH (P = 0.03). Mortality was twice among those with PH, compared to those without PH. This is consistent with study by Yigla et al. [4] and Ramasubbu et al., [21] which also showed higher mortality among those with PH.
Limitations of the study
In our study, sample size was small, AVF flow rate and CO could not be assessed, RV catheterization study could not be performed as most of the patients were not willing.
Conclusion
Our study concludes that substantial number of the patients with CKD develops PH. HFrEF and HFpEF are the strongest risk factors. Hence, PH in CKD is predominantly WHO group 2. Thus, PH can be considered as a reflection of cardiorenal syndrome type 4. The other factors contributing to it are anemia, volume overload, and increased calcium phosphate product. PH may be a cause for refractory dyspnea, edema, and ascites in patients with CKD. Long-standing PH is associated with increased morbidity and mortality. Estimation and follow-up of PASP by Doppler echocardiography may be indicated in all the patients with CKD, especially ESRD.
Financial support and sponsorship
Nil
Conflicts of interest
There are no conflicts of interest.
